Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target (Q38134311)

29 August 2017

title

Role of inflammation in the pathogenesis of heart failure with preserved ejection fraction and its potential as a therapeutic target (English)

1 reference

Heart failure with preserved ejection fraction

29 August 2017

0 references

0 references

1 reference

1 reference

N Glezeva

1

1 reference

29 August 2017

J A Baugh

series ordinal

2

1 reference

29 August 2017

publication date

1 September 2014

1 reference

29 August 2017

published in

Heart Failure Reviews

1 reference

29 August 2017

volume

19

1 reference

29 August 2017

issue

5

1 reference

29 August 2017

page(s)

681-694

1 reference

ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Recommendations for the evaluation of left ventricular diastolic function by echocardiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Trends in prevalence and outcome of heart failure with preserved ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Heart failure with preserved ejection fraction: current understanding and emerging concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Prevalence, clinical characteristics, quality of life, and prognosis of patients with congestive heart failure and isolated left ventricular diastolic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Treatment of heart failure with normal ejection fraction: an inconvenient truth!

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Large animal models for diastolic dysfunction and diastolic heart failure-a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Hypertension as an underlying factor in heart failure with preserved ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Lifetime Risk for Developing Congestive Heart Failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Molecular and cellular basis for diastolic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Diastolic dysfunction in hypertensive hearts: roles of perivascular inflammation and reactive myocardial fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

What mechanisms underlie diastolic dysfunction in heart failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

New concepts in diastolic dysfunction and diastolic heart failure: Part I: diagnosis, prognosis, and measurements of diastolic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Diastolic heart failure can be diagnosed by comprehensive two-dimensional and Doppler echocardiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Diagnostic criteria for diastolic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

ECM remodeling in hypertensive heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Patterns of myocardial fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Inflammatory mediators and the failing heart: past, present, and the foreseeable future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

A glossary of circulating cytokines in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Immune and inflammatory mechanisms of atherosclerosis (*)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Exploring the full spectrum of macrophage activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Macrophage plasticity and polarization: in vivo veritas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Effects of chronic arterial hypertension on constitutive and induced intercellular adhesion molecule-1 expression in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Angiotensin-receptor blockade reduces border zone myocardial monocyte chemoattractant protein-1 expression and macrophage infiltration in post-infarction ventricular remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Treatment of heart failure with preserved ejection fraction: have we been pursuing the wrong paradigm?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Monocytic fibroblast precursors mediate fibrosis in angiotensin-II-induced cardiac hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Critical role of monocyte chemoattractant protein-1 receptor CCR2 on monocytes in hypertension-induced vascular inflammation and remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

CCR2 mediates the uptake of bone marrow-derived fibroblast precursors in angiotensin II-induced cardiac fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

The DOCA-Salt Hypertensive Rat as a Model of Cardiovascular Oxidative and Inflammatory Stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Fibrosis, matrix metalloproteinases, and inflammation in the heart of DOCA-salt hypertensive rats: role of ET(A) receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Rosuvastatin added to standard heart failure therapy improves cardiac remodelling in heart failure rats with preserved ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

C-reactive protein, diastolic dysfunction, and risk of heart failure in patients with coronary disease: Heart and Soul Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Prognostic utility of ST2 in patients with acute dyspnea and preserved left ventricular ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Cardiac fibroblast: the renaissance cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

State of the art: using natriuretic peptide levels in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

B-type natriuretic peptide in cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Progressive cardiac hypertrophy and dysfunction in atrial natriuretic peptide receptor (GC-A) deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Hypertension, cardiac hypertrophy, and sudden death in mice lacking natriuretic peptide receptor A

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Natriuretic peptide receptor 1 expression influences blood pressures of mice in a dose-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Expression of constitutively active guanylate cyclase in cardiomyocytes inhibits the hypertrophic effects of isoproterenol and aortic constriction on mouse hearts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

A genetic model provides evidence that the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Cardiac fibrosis in mice lacking brain natriuretic peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

BNP-induced activation of cGMP in human cardiac fibroblasts: interactions with fibronectin and natriuretic peptide receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Brain natriuretic Peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Mechanical stretch up-regulates the B-type natriuretic peptide system in human cardiac fibroblasts: a possible defense against transforming growth factor-β mediated fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Involvement of the NF-kappa B/matrix metalloproteinase pathway in cardiac fibrosis of mice lacking guanylyl cyclase/natriuretic peptide receptor A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Enhanced activation of pro-inflammatory cytokines in mice lacking natriuretic peptide receptor-A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Myocardial cytokine gene expression is higher in aortic stenosis than in idiopathic dilated cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Cardiac natriuretic peptides gene expression and secretion in inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Parallel gene expressions of IL-6 and BNP during cardiac hypertrophy complicated with diastolic dysfunction in spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Circulating heat shock proteins and inflammatory markers in patients with idiopathic left ventricular dysfunction: their relationships with myocardial and microvascular impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

The relationship between tumor necrosis factor-α, brain natriuretic peptide and atrial natriuretic peptide in patients with chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Modest elevation in BNP in asymptomatic hypertensive patients reflects sub-clinical cardiac remodeling, inflammation and extracellular matrix changes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Brain Natriuretic Peptide (BNP) regulates the production of inflammatory mediators in human THP-1 macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Attenuation of monocyte chemotaxis--a novel anti-inflammatory mechanism of action for the cardio-protective hormone B-type natriuretic peptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Irbesartan in patients with heart failure and preserved ejection fraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Heart failure with normal left ventricular ejection fraction: what is the evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Activation of immune and inflammatory systems in chronic heart failure: novel therapeutic approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Anti-Monocyte Chemoattractant Protein-1 Gene Therapy Attenuates Left Ventricular Remodeling and Failure After Experimental Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Reduced degradation of the chemokine MCP-3 by matrix metalloproteinase-2 exacerbates myocardial inflammation in experimental viral cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Decrease of serum levels of the anti-inflammatory cytokine interleukin-10 in patients with advanced chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Elastin degradation and calcification in an abdominal aorta injury model: role of matrix metalloproteinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Loss or inhibition of uPA or MMP-9 attenuates LV remodeling and dysfunction after acute pressure overload in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Diagnosis of heart failure with preserved ejection fraction: improved accuracy with the use of markers of collagen turnover.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Attenuation of oxidative stress and remodeling by cardiac inhibitor of metalloproteinase protein transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

MMP inhibition modulates TNF-alpha transgenic mouse phenotype early in the development of heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Clinical trial of doxycycline for matrix metalloproteinase-9 inhibition in patients with an abdominal aneurysm: doxycycline selectively depletes aortic wall neutrophils and cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Cardioprotective Function of the Long Pentraxin PTX3 in Acute Myocardial Infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

PI3Kγ Modulates the Cardiac Response to Chronic Pressure Overload by Distinct Kinase-Dependent and -Independent Effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

The role of IL-1 in the pathogenesis of heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Vitamin D status and outcomes in heart failure patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Selective PDE5A inhibition with sildenafil rescues left ventricular dysfunction, inflammatory immune response and cardiac remodeling in angiotensin II-induced heart failure in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Brain natriuretic peptide induces CD8+ T cell death via a caspase 3 associated pathway — Implications following heart transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-013-9405-8

Elevated circulating levels of C-C chemokines in patients with congestive heart failure

21 January 2018

1 reference

12 December 2020

Association between C-reactive protein levels and N-terminal pro-B-type natriuretic peptide in pre-dialysis patients

1 reference

12 December 2020

Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction

1 reference

12 December 2020

Elevated circulating levels of tumor necrosis factor in severe chronic heart failure

1 reference

12 December 2020

Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial

1 reference

12 December 2020

Myocardial Structure and Function Differ in Systolic and Diastolic Heart Failure

1 reference

12 December 2020

Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart

1 reference

12 December 2020

Systemic inflammation in patients with heart failure

1 reference

12 December 2020

Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis

1 reference

12 December 2020

Treatment of experimental viral myocarditis with interleukin-10

1 reference

12 December 2020

Impaired tissue Doppler diastolic function in patients with coronary artery disease: relationship to endothelial damage/dysfunction and platelet activation

1 reference

12 December 2020

Overexpression of interleukin-1 receptor antagonist provides cardioprotection against ischemia-reperfusion injury associated with reduction in apoptosis.

1 reference

12 December 2020

Roles of intercellular adhesion molecule-1 in hypertensive cardiac remodeling

1 reference

12 December 2020

Doxycycline [corrected] inhibits mononuclear cell-mediated connective tissue breakdown

1 reference

12 December 2020

The perindopril in elderly people with chronic heart failure (PEP-CHF) study

1 reference

12 December 2020

Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy

1 reference

12 December 2020

Critical role of monocyte chemoattractant protein-1/CC chemokine ligand 2 in the pathogenesis of ischemic cardiomyopathy

1 reference

12 December 2020

Angiotensin II stimulation of left ventricular hypertrophy in adult rat heart. Mediation by the AT1 receptor

1 reference

12 December 2020

Inflammatory cells and myocardial fibrosis: spatial and temporal distribution in renovascular hypertensive rats

1 reference

12 December 2020

Colocalization of myocardial fibrosis and inflammatory cells in rats

1 reference

12 December 2020

Circulating proinflammatory cytokines and N-terminal pro-brain natriuretic peptide significantly decrease with recovery of left ventricular function in patients with dilated cardiomyopathy

1 reference

12 December 2020

Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study).

1 reference

12 December 2020

Causal link between oxidative stress, inflammation, and hypertension.

1 reference

12 December 2020

Immune activation in chronic heart failure

1 reference

12 December 2020

Markers of Inflammation and Fibrosis Are Related to Cardiovascular Damage in Hypertensive Patients with Metabolic Syndrome

1 reference

12 December 2020

Effect of interleukin-10 on the production of tumor necrosis factor-alpha by peripheral blood mononuclear cells from patients with chronic heart failure

1 reference

12 December 2020

10.1007/S10741-013-9405-8

Identifiers

DOI

1 reference

29 August 2017

1 reference